Last reviewed · How we verify
Sinovac PCV13
Sinovac PCV13 is a vaccine that stimulates the body's immune response to protect against 13 serotypes of pneumococcal disease.
Sinovac PCV13 is a vaccine that stimulates the body's immune response to protect against 13 serotypes of pneumococcal disease. Used for Prevention of invasive pneumococcal disease caused by 13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F).
At a glance
| Generic name | Sinovac PCV13 |
|---|---|
| Sponsor | Sinovac Research and Development Co., Ltd. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by introducing inactivated pneumococcal antigens to the body, which triggers an immune response and helps the body produce antibodies to fight off the bacteria. This vaccine is designed to provide long-term protection against pneumococcal disease, including pneumonia, meningitis, and sepsis.
Approved indications
- Prevention of invasive pneumococcal disease caused by 13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F)
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine (PHASE3)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinovac PCV13 CI brief — competitive landscape report
- Sinovac PCV13 updates RSS · CI watch RSS
- Sinovac Research and Development Co., Ltd. portfolio CI